Bavarian Nordic wins EU approval for Imvanex mpox vaccine in children 2-11

• Bavarian Nordic won European Commission clearance to extend IMVANEX (MVA-BN) use to children aged 2 to under 12.
• The EU label now covers people aged 2 and older for protection against mpox, smallpox, and vaccinia virus disease.
• Decision follows a Phase 2 study in 227 children showing immune responses non-inferior to adults with a similar safety profile.
• The trial was co-funded by the Coalition for Epidemic Preparedness Innovations.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bavarian Nordic A/S published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608070200OMX_____CNEWS_EN_GNW1001256491_en) on August 07, 2026, and is solely responsible for the information contained therein.